GenomeFrontier Presents the 2025 Antibody Therapeutic & The 20th Frontiers in Biomedical Sciences Conference

Abstact:

GenomeFrontier is an innovation-driven therapeutics company that utilizes its proprietary virus-free Quantum Engine™ system to develop groundbreaking gene therapies, which are superior to current virus-based therapies. The Quantum Engine™ integrates four proprietary platforms for (1) design of genetic modifications, (2) improved gene delivery, (3) effective gene integration, and (4) robust expansion of high-quality cells, providing a holistic solution for development and manufacture of novel therapies. Applying the Quantum Engine™ to the production of CAR T cells, GenomeFrontier has developed the Quantum CART (qCART™) system. Its products surpass current CAR T therapies in terms of key attributes of multiplex gene design and enrichment of the most desirable cells (CAR⁺ T_SCM cells). These characteristics ensure clinical efficacy with a better safety profile for both liquid and solid tumor treatments. Using qCART™, GenomeFrontier has established a pipeline of three CAR T cell products. Our first asset, GF-CART01, is a dual targeting armored CAR T cell therapy for B cell malignancies. The product has received IND clearance from the Taiwan FDA, and patients are being enrolled for a Phase I clinical trial. Clinical evidence of GF-CART01 safety and efficacy will establish the qCART™ system as an unsurpassed means of designing and manufacturing multiplex CAR TSCM cell therapies. Additionally, GF-CART03 is under development as a triple targeting, armored CAR T product for the treatment of solid tumors, particularly glioblastoma. Thus, the Quantum Engine™ is poised to unlock the full potential of disruptive gene and cell therapies.